Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH-5: Retatrutide versus tirzepatide in adults with obesity
2024-511450-49-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Retatrutide arm with Tirzepatide comparator arm (2 arms). Primary endpoint: Percent Change from Baseline in Body Weight. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2024-511450-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511450-49-00.